Comparative effectiveness of risankizumab vs. ustekinumab in bio-naïve Crohn's disease patients: A real-world multicentre retrospective cohort study

被引：0
|
作者：
Aldiabat, M. [1 ]
Yarur, A. [2 ]
Peyrin-Biroulet, L. [3 ]
Loftus-Jr, E., V [4 ,5 ]
Colombel, J. F.
Deepak, P. [6 ]
机构：
[1] Washington Univ St Louis, Sch Med, Gastroenterol, St Louis, MO USA
[2] Cedars Sinai Med Ctr, Gastroenterol, Los Angeles, CA USA
[3] Nancy Univ Hosp, Inflammatory Bowel Dis IBD Unit, Vandoeuvre Les Nancy, France
[4] Mayo Clin, Coll Med, Gastroenterol, Rochester, MN USA
[5] Icahn Sch Med Mt Sinai, Gastroenterol, New York, NY USA
[6] Washington Univ, Sch Med St Louis, Gastroenterol, St Louis, MO USA
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.0141
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP102
引用
收藏
页码：i268 / i269
页数：2
相关论文
共 50 条
  • [41] Effectiveness and Safety of Upadacitinib Induction Therapy in Real-World Setting for 234 Patients with Crohn's Disease: A GETAID Multicentre Cohort Study
    Richard, N.
    Amiot, A.
    Seksik, P.
    Altwegg, R.
    Laharie, D.
    Vuitton, L.
    Nachury, M.
    Nancey, S.
    Bouguen, G.
    Gilletta, C.
    Rouillon, C.
    Coffin, B.
    Allez, M.
    Buisson, A.
    Le Berre, C.
    Pelletier, A. L.
    Uzzan, M.
    Caillo, L.
    Sickersen, G.
    Hupe, M.
    Abitbol, V
    Vidon, M.
    Goutorbe, F.
    Amil, M.
    Brixi, H.
    Benezech, A.
    Kwiatek, S.
    Peyrin-Biroulet, L.
    Fumery, M.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1948 - i1950
  • [42] Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study
    Fumery, Mathurin
    Defrance, Antoine
    Roblin, Xavier
    Altwegg, Romain
    Caron, Benedicte
    Hebuterne, Xavier
    Stefanescu, Carmen
    Meyer, Antoine
    Nachury, Maria
    Laharie, David
    Nancey, Stephane
    Le Berre, Catherine
    Serrero, Melanie
    Geyl, Sophie
    Giletta, Cyrielle
    Ah-Soune, Philippe
    Duveau, Nicolas
    Uzzan, Mathieu
    Abitbol, Vered
    Biron, Amelie
    My-Linh Tran-Minh
    Paupard, Thierry
    Vuitton, Lucine
    Elgharabawy, Yasmine
    Peyrin-Biroulet, Laurent
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (04) : 426 - 434
  • [43] Effectiveness of Risankizumab in an Emirati Crohn's Disease Cohort: Real-World Insights on Induction, Maintenance, and Dose Intensification Outcomes
    Alzaabi, M. N.
    Swaid, T. K.
    Ahmed, H. A.
    Alahmed, M. A.
    Omar, N. M.
    Kumar, K. K. C.
    Ahmed, E. F.
    Malik, T. A.
    Quraishi, M. N.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1845 - i1845
  • [44] Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn's disease: a Belgian multicentric cohort study
    Alsoud, D.
    Franchimont, D.
    D'Heygere, F.
    Bossuyt, P.
    Vijverman, A.
    Van Hootegem, P.
    Sabino, J.
    Cremer, A.
    Vermeire, S.
    Ferrante, M.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I516 - I517
  • [45] A Multi-Center Study of the Outcomes of Risankizumab Use Stratified by Prior Ustekinumab Exposure in Patients With Crohn's Disease: A Real-World Experience
    Manski, Scott
    Andreone, Michael
    Swaminathan, Shreya
    Cordero-Baez, Fernando
    Sanchez, Jonathan Colon
    Kantor, Jenna
    Keith, Scott
    Shmidt, Eugenia
    Shivashankar, Raina
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S820 - S821
  • [46] Assessment of real-world effectiveness of risankizumab in patients with moderate-severe Crohn's disease in a global setting
    Dignass, A.
    Joshi, N.
    Lukanova, R.
    Dawod, F.
    Jones, W.
    Kligys, K.
    Zambrano, J. A.
    Song, A.
    Griffith, J.
    Jairath, V
    Bossuyt, P.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i388 - i390
  • [47] P0832 Real-world effectiveness of risankizumab in Crohn's Disease: The UK Experience
    Elford, A.
    Plevris, N.
    Constantine-Cooke, N.
    Shah, K.
    Faloon, S.
    Colwill, M.
    Akbani, U.
    Morgan, H.
    Ghoda, A.
    Radia, C.
    Young, D.
    Morris, S.
    Anwar-Hashim, Z.
    Hassall, J.
    Thomas, M.
    Dyall, L.
    Clough, J.
    Mahmood, T.
    Mohammed, A.
    Rudling, R.
    Dhar, A.
    Gaya, D.
    Verma, A.
    Seenan, J.
    Johnston, E.
    Goel, R.
    Hicks, L.
    Sebastian, S.
    Hale, M.
    Harvey, P.
    Cooney, R.
    Cummings, F.
    Kent, A.
    King, A.
    Limdi, J.
    Sellinger, C.
    Pollok, R.
    Parkes, G.
    Lees, C.
    PAN UK Risankizumab CD Study Grp
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1589 - i1591
  • [48] Comparison of clinical and endoscopic efficacy between vedolizumab and infliximab in bio-naïve patients with ulcerative colitis: a multicenter, real-world study
    Huang, Zhaopeng
    Tang, Jian
    Wu, Ruibin
    Long, Shunhua
    Chen, Wenke
    Lu, Tingna
    Xia, Qiuyue
    Wu, Yanhui
    Yang, Hongsheng
    Yang, Qingfan
    Huang, Zicheng
    Guo, Qin
    Li, Miao
    Gao, Xiang
    Chao, Kang
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2024, 17
  • [49] Real-World Treatment Persistence Among Bio-Na<spacing diaeresis>ive Patients With Ulcerative Colitis Initiated on Ustekinumab or Adalimumab
    Zhdanava, Maryia
    Kachroo, Sumesh
    Shah, Aditi
    Burbage, Sabree
    Korsiak, Jill
    Lefebvre, Patrick
    Diaz, Lilian
    Kerner, Caroline
    Pilon, Dominic
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S725 - S726
  • [50] An Australian Real-World Study of Treatment Persistence of Ustekinumab in Crohn's Disease
    Chien, Tzu Hsiang
    Puig, Andrea
    Khuong, Thang
    Kouhkamari, Mahsa H.
    Che, Samuel
    Huang, Tom Hsun-Wei
    BIOLOGICS-TARGETS & THERAPY, 2021, 15 : 237 - 245
12345